Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT00400374
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00392704
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT00393068
- Locations
- 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00392665
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
- Conditions
- Interventions
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 45
- Registration Number
- NCT00391586
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸Hematology Oncology Associates NM, Albuquerque, New Mexico, United States
🇺🇸Presbyterian Medical Group, Albuquerque, New Mexico, United States
Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)
- Conditions
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Target Recruit Count
- 40
- Registration Number
- NCT00391248
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 133
- Registration Number
- NCT00384826
- Locations
- 🇫🇷
CHU - Pneumologie, Caen, France
🇫🇷Centre F. Baclesse, Caen, France
🇫🇷Centre Hospitalier - Pneumologie, Belfort, France
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00380029
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- OSI Pharmaceuticals
- Target Recruit Count
- 1252
- Registration Number
- NCT00373425
- Locations
- 🇺🇸
Kootenai Cancer Center, Post Falls, Idaho, United States
🇺🇸University of Arkansas for Medical Science, Little Rock, Arkansas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Agennix
- Target Recruit Count
- 100
- Registration Number
- NCT00370383
- Locations
- 🇺🇸
Highlands Oncology Group, Bentonville, Ohio, United States
🇺🇸Signal Point Hematology/Oncology, Middleton, Ohio, United States
🇨🇦Princess Margaret Hospital, Toronto, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.